The Science
What VPAC1 is, the matched Cu-64 / Cu-67 copper pair, the gap in breast cancer, the patient journey, and the human evidence behind it.
Explore the science
Clinical-Stage Theranostics
NuView Life Sciences
Developing the first NV-VPAC1™ theranostic platform for breast cancer.
Initial clinical development is focused on triple-negative breast cancer (TNBC), an aggressive disease with limited targeted treatment options and significant unmet need.
NuView Life Sciences is a clinical-stage theranostics company advancing Targeted Copper Theranostics. Our mission is to change how cancer is diagnosed and treated — one receptor (VPAC1), two copper isotopes (Cu-64 to see the disease, Cu-67 to treat it) — advancing first into triple-negative breast cancer (TNBC), where the need is greatest.
1 receptorVPAC1 — over-expressed on cancer cells
2 isotopesCu-64 to see · Cu-67 to treat
TNBC firstthen to other breast cancer subtypes
Why TNBC first
Where today's targeted toolkit runs out
Triple-negative breast cancer is defined by what it lacks — no estrogen receptor, no progesterone receptor, no HER2 amplification — so the targeted therapies that transformed other breast cancers simply don't apply. VPAC1 is over-expressed on the cancer cell itself, independent of ER, PR and HER2 status.
~10–15%of all breast cancers are triple-negative — the subtype with the fewest targeted options
ER− PR− HER2−no receptor target for hormone- or HER2-directed therapy
97–99%sensitivity for breast cancer detection in peer-reviewed human imaging, reported by Dr. Mathew Thakur and colleagues at Thomas Jefferson University
1
clinical-stage NV-VPAC1 program
2
copper isotopes from one molecule — Copper-64 (Cu-64) emits positrons to image and locate disease on a PET scan, while Copper-67 (Cu-67) emits cell-killing beta particles to treat those same cells. One target, paired to diagnose and treat.
Start Here · The Target
What is VPAC1?
VPAC1 is a marker found on the surface of cancer cells. It shows up early — at the very start of cancer — and in high numbers, while staying low on healthy cells.
VPAC1 serves as a precise molecular target for cancer. Linked to the imaging isotope Copper-64 (Cu-64), it helps identify and visualize disease. Combined with the therapeutic isotope Copper-67 (Cu-67), it delivers targeted treatment to those same cells. One target. Two copper isotopes. A unified theranostic approach to detect and treat cancer.
- Appears early — before many conventional markers
- In high numbers — concentrated on the tumor surface
- On the cancer cell itself — not an indirect signal
Theranostics is proven in other cancers — breast cancer remains open.
| Diagnostic / Therapeutic | Target | Indication | Status |
|---|---|---|---|
| Ga-68 / Lu-177 PSMA | PSMA | Prostate cancer | Approved |
| Ga-68 / Lu-177 DOTATATE | SSTR | Neuroendocrine | Approved |
| Zr-89 / Lu-177 Trastuzumab | HER2 | HER2+ cancers | Clinical |
| Ga-68 / Lu-177 FAPI | FAP | Solid tumors | Clinical |
| Cu-64 / Cu-67 NV-VPAC1 | VPAC1 | Breast cancer | Emerging |
NV-VPAC1 is in clinical development.
Explore NuView
The science, the programs, and the opportunity
A focused look at what VPAC1 is, how our matched copper pair works, and why this is a meaningful gap in breast cancer — for clinicians and investors alike.
Our Programs
The lead NV-VPAC1 theranostic for TNBC, Cu-64 PET imaging, and our broader pipeline — including liquid biopsy and point-of-care diagnostics.
See the programsFor Investors
Peer-reviewed human data, IP estate, and regulatory status (FDA Pre-IND). Request the NV-VPAC1 white paper and scientific dossier.
Investor relations
VPAC1
One platform. Diagnosis to therapy.
The NV-VPAC1 platform brings the story together — how a single proprietary molecule images cancer with Cu-64 and treats it with Cu-67, delivering binary diagnostic synergies and precision therapeutic delivery.
- In vitro & in vivo binary diagnostic synergies
- Precision therapeutic delivery
- Optimized patient treatment planning & delivery
Get In Touch
Let's talk precision oncology
Have a question about our technology, pipeline, or partnership opportunities? Send us a message and a member of our team will respond.
Headquarters10171 Silva Road, San Diego, CA 92021